⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MRK News
Merck & Co., Inc.
HelixIntel Expands HelixCMMS with Fleet Management, Bringing Vehicles, Drivers, and Maintenance Into One Platform
globenewswire.com
MRK
NGG
Merck Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies
businesswire.com
MRK
Merck KGaA, Darmstadt, Germany, Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies
businesswire.com
MRK
Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda
globenewswire.com
ABBV
ALNY
ASTL
AZN
BIIB
BMY
CSL
LLY
GILD
GSK
MRK
NVS
NVO
PFE
REGN
SNY
SUN
TEVA
UPST
VRTX
Women's Clinical Trials & CROs Market Forecast to More Than Double by 2036 as Precision Medicine Reshapes Trial Design
globenewswire.com
PFE
NVS
MRK
JNJ
Alger Russell Innovation Index Updates for Second Quarter 2026
prnewswire.com
ADBE
DOCS
DOX
GNTX
META
MRK
RBLX
TRMB
XYZ
Z
ZS
CORT
DV
GTM
ILMN
NTAP
OKTA
P
QCOM
TDC
TWLO
ZM
Phanes Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Spevatamig in Combination with Chemotherapy for the Frontline Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
prnewswire.com
MRK
Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight
globenewswire.com
BIIB
AMGN
BMY
IMVT
AZN
MRK
CTNT
REGN
GILD
DropGenie Raises Seed+ Financing to Accelerate Commercialization of Its First Product
prnewswire.com
MRK
Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
businesswire.com
MRK